Subcutaneous Immunoglobulin 16.5% (Cutaquig) is Safe and Efficacious at Modified Dosing Regimens in Patients With Primary Immunodeficiency Disease

Authors
Category Primary study
JournalJournal of Allergy and Clinical Immunology
Year 2023
This article has no abstract
Epistemonikos ID: 650e6214703ac446d486d212d13766b9b48ee5ae
First added on: Feb 15, 2025